For example, anti-CTLA-4, anti-PD1 and other immune checkpoint inhibition therapies lead to elevated interferon-gamma (IFNγ) in the tumor microenvironment because of increased IFNγ expression in immune cells [59,60]. This evidence concerns the gene IFNG and neoplasm.